You are here

Theravance

Irenic Capital urges Theravance to conduct review, add shareholder to board

Irenic Capital urges Theravance to conduct review, add shareholder to board

NASDAQ

Flag link:

Theravance declares independence from GSK, crafts $250M plan to buy back its own shares

Theravance declares independence from GSK, crafts $250M plan to buy back its own shares

Endpoints

Flag link:

Theravance gets a fresh start

Theravance gets a fresh start

EP Vantage

Trelegy Ellipta

Flag link:

Theravance Narrows Focus to Multiple System Atrophy Subset Following Mixed Results

Theravance Narrows Focus to Multiple System Atrophy Subset Following Mixed Results

BioSpace

multiple system atrophy

neurogenic orthostatic hypotension

Flag link:

End-of-Year Restructuring Means Layoffs for These Companies

End-of-Year Restructuring Means Layoffs for These Companies

BioSpace

Rigel Pharmaceuticals

Esperion Therapeutics

Acorda Therapeutics

Ziopharm Oncology

Flag link:

Theravance axing 75% of staff, slashing R&D budget after flunking phase 3

Theravance axing 75% of staff, slashing R&D budget after flunking phase 3

Fierce Biotech

clinical trials

Flag link:

Theravance takes a gut punch as J&J-partnered JAK drug flops key test in ulcerative colitis

Theravance takes a gut punch as J&J-partnered JAK drug flops key test in ulcerative colitis

Endpoints

ulcerative colitis

Crohn’s disease

clinical trials

Flag link:

Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903

Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903

Pharmaceutical Business Review

clinical trials

acute lung injury

Flag link:

JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation

JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation

BioSpace

Intercept Pharmaceuticals

Avidity Biosciences

Moderna Therapeutics

Kodiak Sciences

Flag link:

Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance

Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance

BioSpace

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

Yahoo/Benzinga

Akero Therapeutics

Dermavant Sciences

Prevail Therapeutics

Stoke Therapeutics

Flag link:

Layoffs Hit California Biopharma Companies

Layoffs Hit California Biopharma Companies

BioSpace

Flag link:

Theravance Pipeline Strong, Plans Yupelri Launch by Year End

Theravance Pipeline Strong, Plans Yupelri Launch by Year End

Yahoo/Zacks.com

Flag link:

Mylan, Theravance win FDA approval for COPD drug

Mylan, Theravance win FDA approval for COPD drug

Biopharma Dive

Flag link:

FDA Action Alert: Theravance, Mallinckrodt and Aquestive

FDA Action Alert: Theravance, Mallinckrodt and Aquestive

BioSpace

Aquestive Therapeutics

erectile dysfunction

Flag link:

Theravance Biopharma and Cumberland Pharmaceuticals Enter into $25 Million Antibiotic Deal

Theravance Biopharma and Cumberland Pharmaceuticals Enter into $25 Million Antibiotic Deal

Xtalks

Cumberland Pharmaceuticals

hospital-acquired bacterial pneumonia

Flag link:

Can Johnson & Johnson Replace Remicade for $100 Million Upfront?

Can Johnson & Johnson Replace Remicade for $100 Million Upfront?

Motley Fool

inflammatory bowel disease

Flag link:

J&J strikes potential $1B JAK inhibitor deal with Theravance

J&J strikes potential $1B JAK inhibitor deal with Theravance

Biopharma Dive

drug development

Crohn's Disease

ulcerative colitis

Flag link:

Why Amgen, Lilly, J&J Are Interested In These Small Biotechs

Why Amgen, Lilly, J&J Are Interested In These Small Biotechs

Investors Business Daily

Bavarian Nordic

Biohaven Pharmaceuticals

Flag link:

Mylan, Theravance’s inhaled COPD therapy proves safe in late-stage trial

Mylan, Theravance’s inhaled COPD therapy proves safe in late-stage trial

Drug Delivery Business News

clinical trials

Flag link:

Pages